Karyopharm Therapeutics Inc. KPTI
We take great care to ensure that the data presented and summarized in this overview for Karyopharm Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KPTI
View all-
Vanguard Group Inc Valley Forge, PA7.65MShares$5.89 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY5.55MShares$4.27 Million0.36% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$3.93 Million0.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$3.33 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$3.21 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.1MShares$2.39 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.08MShares$1.6 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX2.02MShares$1.55 Million0.1% of portfolio
-
Gsa Capital Partners LLP London, X01.78MShares$1.37 Million0.11% of portfolio
-
C World Wide Group Holding A1.5MShares$1.16 Million0.01% of portfolio
Latest Institutional Activity in KPTI
Top Purchases
Top Sells
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Insider Transactions at KPTI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,675
-0.32%
|
$0
$0.91 P/Share
|
|
Oct 04
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,607
-0.32%
|
$0
$0.88 P/Share
|
|
Sep 04
2024
|
Michael Mano SVP, General Counsel&Secretary |
SELL
Open market or private sale
|
Direct |
3,971
-1.43%
|
$0
$0.72 P/Share
|
|
Sep 04
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,667
-0.32%
|
$0
$0.72 P/Share
|
|
Sep 04
2024
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
7,050
-1.77%
|
$0
$0.72 P/Share
|
|
Sep 04
2024
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,356
-1.31%
|
$0
$0.72 P/Share
|
|
Aug 06
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,608
-0.31%
|
$0
$0.93 P/Share
|
|
Jul 30
2024
|
Stuart Poulton EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,883
-0.87%
|
$2,883
$1.06 P/Share
|
|
Jul 05
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,616
-0.31%
|
$0
$0.85 P/Share
|
|
Jun 07
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
231,548
-100.0%
|
$0
$0.95 P/Share
|
|
Jun 06
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
118,452
-33.83%
|
$0
$0.98 P/Share
|
|
Jun 05
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
468,044
-57.21%
|
$0
$0.96 P/Share
|
|
Jun 04
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,592
-0.31%
|
$0
$0.99 P/Share
|
|
Jun 04
2024
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
652
-0.16%
|
$0
$0.99 P/Share
|
|
Jun 04
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
341,040
-29.42%
|
$0
$0.95 P/Share
|
|
Jun 03
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
360,744
-23.73%
|
$360,744
$1.0 P/Share
|
|
May 31
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Indirect |
204,394
-11.85%
|
$0
$0.95 P/Share
|
|
May 06
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,576
-0.31%
|
$3,576
$1.13 P/Share
|
|
Apr 22
2024
|
Reshma Rangwala EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,789
-1.94%
|
$6,789
$1.17 P/Share
|
|
Apr 04
2024
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
3,563
-0.31%
|
$3,563
$1.29 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.47M shares |
|---|
| Open market or private sale | 2.03M shares |
|---|